$ 1.83
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease. Among their key offerings is Epi+Gen CHD, a test designed to assess an individual's three-year risk for developing symptomatic coronary heart disease. This company, headquartered in Chicago, Illinois, was established in 2017.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA.
Data is available to registered users only